TY - JOUR
T1 - Identifying risk factors for depression and anxiety symptoms in patients with chronic lymphocytic leukemia
AU - Robbertz, Abigail S.
AU - Weiss, David M.
AU - Awan, Farrukh T.
AU - Byrd, John C.
AU - Rogers, Kerry A.
AU - Woyach, Jennifer A.
N1 - Funding Information:
This research was supported by an Ohio State University College of Arts and Sciences Undergraduate Research Scholarship, Edward M. Alkire Research Award, and an Undergraduate Research Office Summer Fellowship awarded to A.S. Robbertz. Acknowledgments
Funding Information:
Abigail S. Robbertz has no COI. Dave M. Weiss received funding from Pelatonia. Dr. Farrukh T. Awan received funding from AbbVie, Pharmacyclics, Janssen, AstraZeneca, Sunesis, Innate Pharma, Genetech, and Gilead. Dr. John C. Byrd has no COI. Dr. Kerry A. Rogers received funding from Genetech and Acerta. Dr. Jennifer A. Woyach received funding from Morphosys, AbbVie, Karyopharm, Pharmacyclics, Janssen, and Acerta.
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Purpose: This study assessed whether empirically supported risk factors can identify future depression and anxiety symptoms in a specific cancer type, chronic lymphocytic leukemia (CLL). Methods: Patients enrolled in a CLL treatment clinical trial (N = 106) participated at baseline following informed consent and prior to treatment initiation. Risk factors with empirical support (personal or family psychiatric history, recurrent, advanced or progressive disease, low socioeconomic status, gender, medical comorbidities, and single marital status) and additional risk factors (cancer-specific stress, social contacts, negative life events, absolute lymphocyte counts, treatment group, and fatigue) were measured at baseline to predict depression and anxiety symptoms at 12 months. Results: Data show 14% (n = 15) and 12% (n = 13) of patients experienced moderate-severe depression and anxiety symptoms, respectively. Multiple linear regression analyses found medical comorbidities predicted 12-month anxiety symptoms (p < 0.05). Also, negative life events predicted depression and anxiety symptoms and fatigue predicted depression symptoms (p < 0.05). Conclusion: Empirically supported risk factors associated with depression and anxiety symptoms are limited in predicting future depression and anxiety symptoms beyond initial screening in patients with CLL. In addition to levels of depression and anxiety symptoms at baseline, negative life events, higher levels of fatigue, and greater medical comorbidities were associated with future depression or anxiety symptoms in patients with CLL.
AB - Purpose: This study assessed whether empirically supported risk factors can identify future depression and anxiety symptoms in a specific cancer type, chronic lymphocytic leukemia (CLL). Methods: Patients enrolled in a CLL treatment clinical trial (N = 106) participated at baseline following informed consent and prior to treatment initiation. Risk factors with empirical support (personal or family psychiatric history, recurrent, advanced or progressive disease, low socioeconomic status, gender, medical comorbidities, and single marital status) and additional risk factors (cancer-specific stress, social contacts, negative life events, absolute lymphocyte counts, treatment group, and fatigue) were measured at baseline to predict depression and anxiety symptoms at 12 months. Results: Data show 14% (n = 15) and 12% (n = 13) of patients experienced moderate-severe depression and anxiety symptoms, respectively. Multiple linear regression analyses found medical comorbidities predicted 12-month anxiety symptoms (p < 0.05). Also, negative life events predicted depression and anxiety symptoms and fatigue predicted depression symptoms (p < 0.05). Conclusion: Empirically supported risk factors associated with depression and anxiety symptoms are limited in predicting future depression and anxiety symptoms beyond initial screening in patients with CLL. In addition to levels of depression and anxiety symptoms at baseline, negative life events, higher levels of fatigue, and greater medical comorbidities were associated with future depression or anxiety symptoms in patients with CLL.
KW - Anxiety
KW - CLL
KW - Cancer
KW - Depression
UR - http://www.scopus.com/inward/record.url?scp=85069506345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069506345&partnerID=8YFLogxK
U2 - 10.1007/s00520-019-04991-y
DO - 10.1007/s00520-019-04991-y
M3 - Article
C2 - 31332513
AN - SCOPUS:85069506345
SN - 0941-4355
VL - 28
SP - 1799
EP - 1807
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
IS - 4
ER -